Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer
The FASEB Journal · 31.03.2025 · 39 (6)
DOI: 10.1096/fj.202500047r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 22.03.2025. Verfasst von Qiaojian Zou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Copper, Antineoplastic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation (China Postdoctoral Foundation Project).
Abstract (Originalsprache)
Cuproptosis is a novel form of regulated cell death triggered by copper ion and copper ionophore. While cuproptosis has been actively explored as a potential target for cancer therapy, its role in ovarian cancer (OC) still remains unclear. In this study, we demonstrate that cuproptosis inhibits OC cell proliferation, migration, and invasion through FDX1 regulation and suppresses tumor growth in a mouse model. We also confirm that cuproptosis enhances OC sensitivity to cisplatin treatment both in vivo and in vitro. Moreover, our findings reveal that cuproptosis affects cholesterol biosynthesis in OC cells, with cholesterol playing a crucial role in its cytotoxic effect. Taken together, our results elucidate the effect of cuproptosis in OC and suggest it as a promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Obstetrics and Gynecology, Guangdong Provincial Clinical Research Center for Obstetrical and Gynecological Diseases, Guangzhou, China.
ORCID-Profile: Qiaojian Zou, Yili Chen, Duo Liu, Qiqiao Du, Chunyu Zhang, Qiuwen Mai, Xiaojun Wang, Xiaoying Lin, Qianrun Chen, Mengxun Wei, Chudan Chi, Shuzhong Yao, Junxiu Liu
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | National Natural Science Foundation of China (NSFC)
- China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
- GDSTC | Basic and Applied Basic Research Foundation of Guangdong Province
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Zou, Q., Chen, Y., Liu, D., Du, Q., Zhang, C., Mai, Q., Wang, X., Lin, X., Chen, Q., Wei, M., Chi, C., Yao, S., & Liu, J. (2025). Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer. The FASEB Journal, 39(6). https://doi.org/10.1096/fj.202500047r
Vancouver
Zou Q, Chen Y, Liu D, Du Q, Zhang C, Mai Q, et al. Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer. The FASEB Journal. 2025;39(6). doi:10.1096/fj.202500047r
BibTeX
@article{Zou2025,
author = {Zou, Qiaojian and Chen, Yili and Liu, Duo and Du, Qiqiao and Zhang, Chunyu and Mai, Qiuwen and Wang, Xiaojun and Lin, Xiaoying and Chen, Qianrun and Wei, Mengxun and Chi, Chudan and Yao, Shuzhong and Liu, Junxiu},
title = {Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {6},
doi = {10.1096/fj.202500047r}
}
EUVIMED